Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

Gelijkaardige items

• Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
  door: Frigault, Melanie M., et al.
  Gepubliceerd in: (2020)
• Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer
  door: Bahcall, Magda, et al.
  Gepubliceerd in: (2016)
• EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1(st) generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples
  door: Rangachari, Deepa, et al.
  Gepubliceerd in: (2019)
• Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
  door: Jixian Li, et al.
  Gepubliceerd in: (2025-07-01)
• Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab
  door: Nakamura, Yoshiaki, et al.
  Gepubliceerd in: (2020)